How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,015 results for

Ketoconazole

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

4981. Ketoconazole (PubMed)

Ketoconazole 4063919 1986 01 21 2018 11 13 0820-3946 133 11 1985 Dec 01 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Ketoconazole. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. 1117-8 eng Journal Article Canada CMAJ 9711805 0820-3946 R9400W927I Ketoconazole AIM IM Administration, Oral Child Drug Tolerance Humans Ketoconazole administration & dosage metabolism therapeutic use Mycoses drug therapy Tissue

Full Text available with Trip Pro

1985 Canadian Medical Association Journal

4982. Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase. (PubMed)

Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase. In cultured hepatocytes conversion of [4-14C]cholesterol into bile acids was dose dependently reduced by the antimycotic drug ketoconazole, giving half-maximal inhibition at 10 microM ketoconazole in rat hepatocytes and at 1 microM in human hepatocytes. No change was observed in the ratio of produced cholic, beta-muricholic, and chenodeoxycholic acid (...) with increasing amounts of the drug. Conversion of [4-14C]7 alpha-hydroxycholesterol, an intermediate of bile acid pathway, to bile acids was not affected by ketoconazole. These results together with kinetic studies with rat liver microsomes, demonstrating noncompetitive inhibition (Ki = 0.4 microM), indicate that cholesterol 7 alpha-hydroxylase is the main site of inhibition. In bile-diverted rats a single dose of ketoconazole (50 mg/kg) dramatically impaired bile flow and biliary bile acid output (92

Full Text available with Trip Pro

1986 Journal of Clinical Investigation

4983. Enhancement of ketoconazole penetration across the blood-brain barrier of mice by dimethyl sulfoxide. (PubMed)

Enhancement of ketoconazole penetration across the blood-brain barrier of mice by dimethyl sulfoxide. Mice were treated with ketoconazole with and without dimethyl sulfoxide. Concentrations of ketoconazole at 3 and 5 h after treatment were significantly higher in serum (P less than 0.05) and brain tissue homogenate (P less than 0.01) of mice treated with dimethyl sulfoxide than in those of mice not treated with dimethyl sulfoxide.

Full Text available with Trip Pro

1986 Antimicrobial Agents and Chemotherapy

4984. Broth dilution testing of Candida albicans susceptibility to ketoconazole. (PubMed)

Broth dilution testing of Candida albicans susceptibility to ketoconazole. We performed a detailed investigation of the kinetics of ketoconazole activity in the setting of broth dilution testing of Candida albicans susceptibility. Turbidimetric readings reflected parallel quantitative colony counts. The method of endpoint determination markedly affected the results. Determinations of 50% inhibitory concentrations clearly separated the ketoconazole-resistant strains from the susceptible strains.

Full Text available with Trip Pro

1987 Antimicrobial Agents and Chemotherapy

4985. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. (PubMed)

Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Fluconazole (UK 49,858), a new orally administered bis-triazole, was compared with ketoconazole for activity in synthetic broth dilution susceptibility tests against Candida albicans and also in treatment of experimental systemic candidal infections in rats. In vitro studies indicated that fluconazole activity is less sensitive to acidic medium than is that of ketoconazole. At physiologic pH (...) , fluconazole was approximately 16-fold less active than ketoconazole against 35 representative isolates of C. albicans. Two additional isolates (K-1 and K-3) recovered from patients who had failed ketoconazole therapy were 32- to 64-fold more resistant than the median of each drug for other isolates. In animal studies, fluconazole was very effective in prolonging survival of rats infected with a representative candidal strain. With an inoculum sufficient to kill 29 of 38 sham-treated animals, only 1 of 18

Full Text available with Trip Pro

1986 Antimicrobial Agents and Chemotherapy

4986. Effect of ketoconazole in combination with other inhibitors of sterol synthesis on fungal growth. (PubMed)

Effect of ketoconazole in combination with other inhibitors of sterol synthesis on fungal growth. The effect of combination of ketoconazole with other sterol synthesis inhibitors on fungal growth was tested against a variety of fungi selected for resistance to ketoconazole. All of the sterol inhibitors, at concentrations lower than their MICs, caused an increase greater than fourfold in the ketoconazole susceptibility of some fungi. Some of the sterol synthesis inhibitors showed this effect (...) with ketoconazole at levels that may be achieved clinically.

Full Text available with Trip Pro

1985 Antimicrobial Agents and Chemotherapy

4987. Ketoconazole Use in Tinea Versicolor (PubMed)

Ketoconazole Use in Tinea Versicolor 18750333 2010 06 30 2018 11 13 0093-0415 147 4 1987 Oct The Western journal of medicine West. J. Med. Ketoconazole use in tinea versicolor. 457 Jacobs P H PH eng Journal Article United States West J Med 0410504 0093-0415 1987 10 1 0 0 1987 10 1 0 1 1987 10 1 0 0 ppublish 18750333 PMC1025909 Cutis. 1984 Nov;34(5):470-1 6094116 Int J Dermatol. 1982 Jan-Feb;21(1):8-11 7061193

Full Text available with Trip Pro

1987 Western Journal of Medicine

4988. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. (PubMed)

Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. We have investigated the growth-inhibitory effects of two ergosterol biosynthesis inhibitors, the dioxolane imidazole ketoconazole and the allylamine SF 86-327, alone and in combination, on the proliferative stages of Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas' disease. Proliferation of epimastigotes in liver infusion-tryptose (...) medium at 28 degrees C was immediately arrested by any of these drugs at greater than or equal to 3 x 10(-5) M; cell lysis occurred 24 h later. Below that concentration, SF 86-327 at concentrations down to 1 x 10(-6) M stopped growth after 48 h. In contrast, ketoconazole slowed cell growth only moderately, but proliferation finally stopped and cell lysis occurred after 120 h at 3 x 10(-6) M. Synergistic effects could be observed when the two drugs were used in combination: the concentration of SF 86

Full Text available with Trip Pro

1988 Antimicrobial Agents and Chemotherapy

4989. Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. (PubMed)

Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. ICI 195,739, a novel orally active triazole, proved 50 times as potent as ketoconazole, produced a clinical cure, and completely eradicated residual infection in a murine model of pulmonary blastomycosis. No other previously tested azole has shown similar activity. Fungicidal activity against Blastomyces dermatitidis was seen in vitro at concentrations 1/40

Full Text available with Trip Pro

1989 Antimicrobial Agents and Chemotherapy

4990. Preoperative ketoconazole therapy for adrenocortical carcinoma. (PubMed)

Preoperative ketoconazole therapy for adrenocortical carcinoma. 2743227 1989 08 11 2018 11 13 0820-3946 141 2 1989 Jul 15 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Preoperative ketoconazole therapy for adrenocortical carcinoma. 131-3 Sinnaeve L J LJ Department of Medicine, St. Joseph's Health Centre, Western Ontario, London. Becks G P GP eng Case Reports Journal Article Canada CMAJ 9711805 0820-3946 R9400W927I Ketoconazole AIM IM Adrenal (...) Cortex Neoplasms drug therapy surgery Carcinoma drug therapy surgery Combined Modality Therapy Drug Evaluation Female Humans Ketoconazole therapeutic use Middle Aged Neoplasm Recurrence, Local drug therapy Premedication 1989 7 15 1989 7 15 0 1 1989 7 15 0 0 ppublish 2743227 PMC1269337 JAMA. 1985 Apr 26;253(16):2413-4 3981770 Arch Intern Med. 1985 May;145(5):863-4 2986567 Lancet. 1985 Jul 20;2(8447):151-2 2410748 J Clin Endocrinol Metab. 1986 Sep;63(3):766-9 3755445 J Steroid Biochem. 1986 Jan;24(1

Full Text available with Trip Pro

1989 CMAJ: Canadian Medical Association Journal

4991. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. (PubMed)

Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. We have studied the antiproliferative effects of mevinolin (lovastatin), an inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, on the protozoan parasite Trypanosoma (Schizotrypanum) cruzi and its ability to potentiate the action of specific ergosterol biosynthesis inhibitors, such as ketoconazole and terbinafine (...) , both in vitro and in vivo. Against the epimastigote form in vitro, mevinolin produced a dose-dependent reduction of the growth rate up to 25 microM, but at 50 and 75 microM, complete growth arrest and cell lysis took place after 144 and 96 h, respectively. A systematic study of the effects of mevinolin combined with ketoconazole and terbinafine, which act at different points in the ergosterol biosynthesis pathway, on the proliferation of epimastigotes indicated a synergic action, as shown

Full Text available with Trip Pro

1993 Antimicrobial Agents and Chemotherapy

4992. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. (PubMed)

Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. 8002145 1995 01 26 2013 11 21 0011-9059 33 10 1994 Oct International journal of dermatology Int. J. Dermatol. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. 726-9 Stengel F F Dermatology Division, CEMIC--University of Buenos Aires Medical School, Argentina. Robles-Soto M M Galimberti R R Suchil P P eng Clinical Trial Comparative Study Journal Article (...) Multicenter Study Randomized Controlled Trial England Int J Dermatol 0243704 0011-9059 0 Placebos 8VZV102JFY Fluconazole R9400W927I Ketoconazole IM Int J Dermatol. 1994 Oct;33(10):701 8002137 Int J Dermatol 1995 Mar;34(3):215 Adult Candida isolation & purification Candidiasis, Cutaneous drug therapy microbiology Double-Blind Method Female Fluconazole administration & dosage adverse effects therapeutic use Follow-Up Studies Humans Ketoconazole administration & dosage adverse effects therapeutic use Male

1995 International Journal of Dermatology Controlled trial quality: uncertain

4993. Pityriasis versicolor with ketoconazole. (PubMed)

Pityriasis versicolor with ketoconazole. 2654210 1989 06 09 2018 04 14 0190-9622 20 4 1989 Apr Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. Pityriasis versicolor with ketoconazole. 703-5 Zaias N N eng Clinical Trial Journal Article Randomized Controlled Trial United States J Am Acad Dermatol 7907132 0190-9622 R9400W927I Ketoconazole IM Administration, Oral Adolescent Adult Chemical and Drug Induced Liver Injury etiology Clinical Trials as Topic Double-Blind Method (...) Humans Ketoconazole administration & dosage adverse effects Middle Aged Random Allocation Risk Factors Tinea Versicolor drug therapy 1989 4 1 1989 4 1 0 1 1989 4 1 0 0 ppublish 2654210 S0190-9622(89)80166-5

1989 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

4994. Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial. (PubMed)

Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial. 8438428 1993 03 25 2013 11 21 0041-1345 25 1 Pt 1 1993 Feb Transplantation proceedings Transplant. Proc. Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial. 591-4 First M R MR Division of Nephrology and Hypertension, University of Cincinnati Medical Center, OH 45267-0585. Schroeder T J TJ Michael (...) A A Hariharan S S Weiskittel P P Alexander J W JW eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Transplant Proc 0243532 0041-1345 83HN0GTJ6D Cyclosporine 97C5T2UQ7J Cholesterol AYI8EX34EU Creatinine MRK240IY2L Azathioprine R9400W927I Ketoconazole VB0R961HZT Prednisone IM Azathioprine blood therapeutic use Blood Urea Nitrogen Cholesterol blood Creatinine blood Cyclosporine therapeutic use Drug Therapy, Combination Follow-Up

1993 Transplantation proceedings Controlled trial quality: uncertain

4995. Treatment of chronic mucocutaneous candidosis with ketoconazole: preliminary results of a controlled, double-blind clinical trial. (PubMed)

Treatment of chronic mucocutaneous candidosis with ketoconazole: preliminary results of a controlled, double-blind clinical trial. 6255538 1981 02 19 2013 11 21 0162-0886 2 4 1980 Jul-Aug Reviews of infectious diseases Rev. Infect. Dis. Treatment of chronic mucocutaneous candidosis with ketoconazole: preliminary results of a controlled, double-blind clinical trial. 599 Kirkpatrick C H CH Petersen E A EA Alling D W DW eng Clinical Trial Journal Article Randomized Controlled Trial United States (...) Rev Infect Dis 7905878 0162-0886 0 Imidazoles 0 Piperazines R9400W927I Ketoconazole IM Adolescent Adult Candidiasis drug therapy Candidiasis, Chronic Mucocutaneous drug therapy Child Clinical Trials as Topic Double-Blind Method Female Humans Imidazoles therapeutic use Ketoconazole Male Piperazines therapeutic use Time Factors 1980 7 1 1980 7 1 0 1 1980 7 1 0 0 ppublish 6255538

1981 Reviews Of Infectious Diseases Controlled trial quality: predicted high

4996. Ketoconazole versus mepartricin for the prevention of Candida infections in the immunocompromised host. (PubMed)

Ketoconazole versus mepartricin for the prevention of Candida infections in the immunocompromised host. 6305809 1983 08 17 2013 11 21 0390-6078 68 2 1983 Mar-Apr Haematologica Haematologica Ketoconazole versus mepartricin for the prevention of Candida infections in the immunocompromised host. 226-32 Van Lint M T MT Bacigalupo A A Frassoni F F Podestà M M Soro O O Grazi G G Marmont A A eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S (...) . Gov't Italy Haematologica 0417435 0390-6078 0 Imidazoles 0 Piperazines 0 Polyenes 11121-32-7 Mepartricin R9400W927I Ketoconazole IM Bone Marrow Transplantation Candidiasis drug therapy etiology Humans Imidazoles administration & dosage Immunosuppression adverse effects Ketoconazole Mepartricin administration & dosage Piperazines administration & dosage Polyenes administration & dosage 1983 3 1 1983 3 1 0 1 1983 3 1 0 0 ppublish 6305809

1983 Haematologica Controlled trial quality: uncertain

4997. The pharmacokinetics of ketoconazole in severely immunocompromised patients. (PubMed)

The pharmacokinetics of ketoconazole in severely immunocompromised patients. 6298171 1983 04 07 2013 11 21 0305-7453 10 6 1982 Dec The Journal of antimicrobial chemotherapy J. Antimicrob. Chemother. The pharmacokinetics of ketoconazole in severely immunocompromised patients. 489-96 Hann I M IM Prentice H G HG Keaney M M Corringham R R Blacklock H A HA Fox J J Gascoigne E E Van Cutsem J J eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't England J (...) Antimicrob Chemother 7513617 0305-7453 0 Antifungal Agents 0 Imidazoles 0 Piperazines R9400W927I Ketoconazole IM Adult Antifungal Agents metabolism Bone Marrow Transplantation Female Humans Imidazoles metabolism Immune Tolerance Ketoconazole Kinetics Leukemia immunology metabolism Male Piperazines metabolism 1982 12 1 1982 12 1 0 1 1982 12 1 0 0 ppublish 6298171

1983 The Journal of antimicrobial chemotherapy Controlled trial quality: uncertain

4998. Tinea versicolor: treatment and prophylaxis with ketoconazole. (PubMed)

Tinea versicolor: treatment and prophylaxis with ketoconazole. 6291861 1983 01 19 2013 11 21 0011-4162 30 4 1982 Oct Cutis Cutis Tinea versicolor: treatment and prophylaxis with ketoconazole. 542-5, 550 Faergemann J J Djärv L L eng Clinical Trial Journal Article Randomized Controlled Trial United States Cutis 0006440 0011-4162 0 Antifungal Agents 0 Imidazoles 0 Piperazines R9400W927I Ketoconazole IM Adolescent Adult Aged Antifungal Agents therapeutic use Female Follow-Up Studies Humans (...) Imidazoles therapeutic use Ketoconazole Male Middle Aged Piperazines therapeutic use Random Allocation Recurrence Tinea Versicolor drug therapy prevention & control 1982 10 1 1982 10 1 0 1 1982 10 1 0 0 ppublish 6291861

1983 Cutis Controlled trial quality: uncertain

4999. The successful treatment of pityriasis versicolor by systemic ketoconazole. (PubMed)

The successful treatment of pityriasis versicolor by systemic ketoconazole. 6282946 1982 08 14 2018 04 14 0190-9622 6 1 1982 Jan Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. The successful treatment of pityriasis versicolor by systemic ketoconazole. 24-5 Urcuyo F G FG Zaias N N eng Clinical Trial Journal Article Randomized Controlled Trial United States J Am Acad Dermatol 7907132 0190-9622 0 Antifungal Agents 0 Imidazoles 0 Piperazines 0 Tablets R9400W927I Ketoconazole (...) IM Administration, Oral Adolescent Adult Antifungal Agents administration & dosage therapeutic use Clinical Trials as Topic Double-Blind Method Drug Administration Schedule Humans Imidazoles administration & dosage therapeutic use Ketoconazole Male Middle Aged Nicaragua Piperazines administration & dosage therapeutic use Tablets Tinea Versicolor drug therapy 1982 1 1 1982 1 1 0 1 1982 1 1 0 0 ppublish 6282946 S0190-9622(82)80198-9

1982 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

5000. Treatment of dandruff with a 2% ketoconazole scalp gel. A double-blind placebo-controlled study. (PubMed)

Treatment of dandruff with a 2% ketoconazole scalp gel. A double-blind placebo-controlled study. 3533805 1986 12 12 2013 11 21 0011-9059 25 8 1986 Oct International journal of dermatology Int. J. Dermatol. Treatment of dandruff with a 2% ketoconazole scalp gel. A double-blind placebo-controlled study. 541 Cauwenbergh G G De Doncker P P Schrooten P P Degreef H H eng Clinical Trial Controlled Clinical Trial Journal Article Randomized Controlled Trial England Int J Dermatol 0243704 0011-9059 0 (...) Gels R9400W927I Ketoconazole IM Adolescent Adult Clinical Trials as Topic Double-Blind Method Female Gels Humans Ketoconazole administration & dosage therapeutic use Male Middle Aged Random Allocation Scalp Dermatoses drug therapy 1986 10 1 1986 10 1 0 1 1986 10 1 0 0 ppublish 3533805

1986 International Journal of Dermatology Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>